Clinical validation of a new diagnostic and monitoring PoC medical device based on quantification of biomarkers in tear fluids to improve the quality of eye health care

Projektinformationen

eyePoC

ID Finanzhilfevereinbarung: 652132

DOI 10.3030/652132

Abgeschlossenes Projekt

EK-Unterschriftsdatum 24 Oktober 2014

Startdatum 1 Oktober 2014

Enddatum 31 März 2015

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

HORUS PHARMA SAS
France

Ziel

Ocular diseases are not only relevant social, sanitary and economic issues, but also a growing market opportunity in an increasingly ageing population. Ophthalmology is a health care area where the availability of easy to use point of care (PoC) medical devices based on biomarkers is fundamental for improving patient vision care, reducing number and frequency of sick leave and disability due to visual problems and for getting a significant reduction of overcrowding of ophthalmology units at health systems. The use of medical devices able to detect and measure biomarkers in human samples in a fast and non-invasive method will allow the easy introduction of these systems at the doctor’s office, thus enabling diagnosis of diseases in an objective manner and accurately monitoring of treatments effectiveness to be introduced into the standard clinical protocols.
The present project is aimed to the clinical validation and market introduction of a device previously developed for ocular surface diseases (OSDs), named Tear Monitor and focused on diagnosis and monitoring of the Dry Eye and inflammation by measuring biomarkers in tears. For this purpose, two European SMEs specialised on ophthalmology establish a collaborative partnership to joint their respective expertises in a complementary synergism to reach the objectives proposed. Horus Pharma, a French pharmaceutical company, specialised on production, distribution and sales of pharmaceutical and biotech products for eye therapy and diagnostic; and Bioftalmik, a Spanish company specialised on biomarker discovery and development of medical devices for ophthalmology applications.
This project is crucial for the economic growth and international expansion of both companies and constitutes the base for strategic development in the immediate future.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › clinical medicine › ophthalmology

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

HORUS PHARMA SAS

• Netto-EU-Beitrag: € 50 000,00
• Adresse: 148 AVENUE GEORGES GUYNEMER ; 6700 Saint-Laurent-Du-Var ; Frankreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Corse › Corse › Corse-du-Sud
• Region: Corse › Corse › Corse-du-Sud
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00

Beteiligte (1)

BIOFTALMIK S.L.

Spanien

• Netto-EU-Beitrag: € 0,00
• Adresse: PARQUE TECNOLOGICO BIZKAIA EDIFICIO 800 2 PLANTA ; 48160 DERIO
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Noreste › País Vasco › Bizkaia
• Region: Noreste › País Vasco › Bizkaia
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: Keine Daten